1 results match your criteria: "OPERA Clinical and Epidemiological Advisory Board[Affiliation]"
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Clin Drug Investig
January 2017
OPERA Clinical and Epidemiological Advisory Board, Epividian Inc., Durham, NC, USA.
Article Synopsis
- The standard HIV treatment involves a three-drug regimen, with DRV/r as the preferred protease inhibitor for antiretroviral-naïve patients.
- This study analyzed the effectiveness of ABC/3TC combined with DRV/r versus other protease inhibitors in treatment-experienced patients.
- Results showed that both groups were similar at the start, but those taking ABC/3TC + DRV/r had better outcomes over time, particularly in achieving viral load suppression.